Spectrum Pharmaceuticals Announces FDA Approval of FUSILEV's Ready-to-Use Formulation

Spectrum Pharmaceuticals SPPI today announced that the U.S. Food and Drug Administration has approved the Company's Supplemental New Drug Application for FUSILEV Injection. Unlike the currently available lyophilized product, this approval is for a “Ready-to-Use” formulation of FUSILEV for Injection.